Last reviewed · How we verify
AGN-210961 Formulation 7
AGN-210961 Formulation 7 is a drug that targets the PCSK9 protein to lower LDL cholesterol.
AGN-210961 Formulation 7 is a drug that targets the PCSK9 protein to lower LDL cholesterol. Used for Hypercholesterolemia.
At a glance
| Generic name | AGN-210961 Formulation 7 |
|---|---|
| Sponsor | Allergan |
| Drug class | PCSK9 inhibitor |
| Target | PCSK9 |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 2 |
Mechanism of action
By inhibiting PCSK9, AGN-210961 reduces the amount of LDL cholesterol in the blood, thereby lowering the risk of cardiovascular events. This is achieved through a mechanism of action that is similar to other PCSK9 inhibitors, such as alirocumab and evolocumab.
Approved indications
- Hypercholesterolemia
Common side effects
- Injection site reactions
- Musculoskeletal pain
- Fatigue
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AGN-210961 Formulation 7 CI brief — competitive landscape report
- AGN-210961 Formulation 7 updates RSS · CI watch RSS
- Allergan portfolio CI